These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11060827)

  • 1. NK-104: a novel synthetic HMG-CoA reductase inhibitor.
    Kajinami K; Mabuchi H; Saito Y
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2653-61. PubMed ID: 11060827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
    Kajinami K; Takekoshi N; Saito Y
    Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
    Yee LL; Wright EA
    Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
    Yamazaki H; Fujino H; Kanazawa M; Tamaki T; Sato F; Suzuki M; Kitahara M
    Nihon Yakurigaku Zasshi; 2004 May; 123(5):349-62. PubMed ID: 15118259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus.
    Kawai Y; Sato-Ishida R; Motoyama A; Kajinami K
    Drug Des Devel Ther; 2011; 5():283-97. PubMed ID: 21625418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
    Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
    Duggan ST
    Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin - a novel therapeutic milestone.
    Ohbayashi H
    Drugs Today (Barc); 2010 Oct; 46(10):765-75. PubMed ID: 21076713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
    Gotto AM; Moon J
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
    Teramoto T
    Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
    Baker WL; Datta R
    Adv Ther; 2011 Jan; 28(1):13-27. PubMed ID: 21170619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nisvastatin. NK 104, P 872441.
    Drugs R D; 1999 Jun; 1(6):486-7. PubMed ID: 10566091
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
    Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.